Trade

with

Sinovac Biotech Ltd
(NASDAQ: SVA)
AdChoices
5.33
+0.06
+1.14%
After Hours :
5.32
-0.01
-0.19%

Open

5.25

Previous Close

5.27

Volume (Avg)

105.69k (199.85k)

Day's Range

5.23-5.36

52Wk Range

4.51-8.14

Market Cap.

292.86M

Dividend Rate ( Yield )

-

Beta

0.48

Shares Outstanding

55.57M

P/E Ratio (EPS)

50.25 (0.10)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 72.52M

    • Net Income

    • 7.44M

    • Market Cap.

    • 292.86M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 8.33

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.48

    • Forward P/E

    • -86.21

    • Price/Sales

    • 4.19

    • Price/Book Value

    • 2.35

    • Price/Cash flow

    • 85.47

      • EBITDA

      • 17.71M

      • Return on Capital %

      • 2.60

      • Return on Equity %

      • 4.83

      • Return on Assets %

      • 2.60

      • Book Value/Share

      • 2.25

      • Shares Outstanding

      • 55.57M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 10.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -30.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 9.30

          • 63.43

          • Net Income

            5-Year Annual Average

          • -1.50

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 70.67

            • 82.75

            • Pre-Tax Margin

            • 9.06

            • 39.38

            • Net Profit Margin

            • 8.33

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 64.20

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -2.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -4.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.09

              • 0.76

              • Current Ratio

              • 2.28

              • 2.92

              • Quick Ratio

              • 1.93

              • 2.35

              • Interest Coverage

              • 3.01

              • 38.02

              • Leverage Ratio

              • 1.85

              • 2.21

              • Book Value/Share

              • 2.25

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 50.25

                • 188.68

                • P/E Ratio 5-Year High

                • 95.04

                • 634.30

                • P/E Ratio 5-Year Low

                • 15.63

                • 124.82

                • Price/Sales Ratio

                • 4.19

                • 8.72

                • Price/Book Value

                • 2.35

                • 7.95

                • Price/Cash Flow Ratio

                • 85.47

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 4.83

                    (3.60)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 2.60

                    (1.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 4.79

                    (2.20)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 8.23k

                  • 117.08k

                  • Inventory Turnover

                  • 1.14

                  • 1.48

                  • Asset Turnover

                  • 0.31

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  8.74M
                  Operating Margin
                  12.06
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  85.47
                  Ownership

                  Institutional Ownership

                  24.34%

                  Top 10 Institutions

                  20.88%

                  Mutual Fund Ownership

                  6.73%

                  Float

                  69.38%

                  5% / Insider Ownership

                  38.85%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity China Special Situations PLC

                  •  

                    949,300

                  • -11.24

                  • 1.69

                  • iShares Nasdaq Biotechnology

                  •  

                    742,809

                  • 3.08

                  • 1.46

                  • Hartford International Value Fund

                  •  

                    318,976

                  • 16.92

                  • 0.57

                  • Davis Global Fund

                  •  

                    289,268

                  • 0.00

                  • 0.52

                  • Wellington Global Health Care Eq Port

                  •  

                    197,900

                  • -8.80

                  • 0.36

                  • Selected International Fund

                  •  

                    176,360

                  • 0.00

                  • 0.32

                  • PowerShares Golden Dragon China Port

                  •  

                    169,621

                  • 0.00

                  • 0.35

                  • Davis International Fund

                  •  

                    153,485

                  • 0.00

                  • 0.28

                  • PHARMA/wHEALTH W/WELLINGTON

                  •  

                    153,220

                  • -19.24

                  • 0.28

                  • PHARMA/wHEALTH

                  •  

                    128,220

                  • -0.62

                  • 0.23

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    3,945,465

                  • -22.95%

                  • 7.10

                  • Orbimed Advisors, LLC

                  •  

                    1,637,500

                  • 0.00%

                  • 2.95

                  • Davis Selected Advisers

                  •  

                    1,250,546

                  • +0.51%

                  • 2.25

                  • Renaissance Technologies Corp

                  •  

                    1,175,000

                  • +13.89%

                  • 2.11

                  • Visium Asset Management LLC

                  •  

                    1,000,000

                  • 0.00%

                  • 1.80

                  • Fidelity International Ltd

                  •  

                    949,300

                  • -11.24%

                  • 1.71

                  • BlackRock Fund Advisors

                  •  

                    658,481

                  • -2.76%

                  • 1.19

                  • Pictet Asset Management SA

                  •  

                    609,100

                  • +24.79%

                  • 1.10

                  • Sj Strategic Investments LLC

                  •  

                    190,868

                  • -93.18%

                  • 0.34

                  • Pine River Capital Management, L.P.

                  •  

                    182,365

                  • +178.49%

                  • 0.33

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, man...moreufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pan...moredemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.lessless

                  Key People

                  Weidong Yin

                  CEO/Chairman of the Board/Chairman of the Board, Subsidiary/Director/General Manager, Subsidiary/President/Secretary

                  Nan Wang

                  CFO/Vice President

                  Mr. Ming Xia

                  Vice President, Divisional

                  Mr. Simon J. Anderson

                  Director

                  Yuk Lam Lo

                  Director

                  • Sinovac Biotech Ltd

                  • No 39, Shangdi Xi Road

                  • Beijing, 100085

                  • ATG.Map

                  • Phone: +86 1082890088

                  • Fax: +86 1062966910

                  • sinovac.com

                  Incorporated

                  1999

                  Employees

                  715

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: